Photo of Tomasz M. Beer, M.D., F.A.C.P.

Tomasz M. Beer M.D., F.A.C.P.

    • Professor of Medicine, Division of Hematology/Medical Oncology School of Medicine
    • Grover C. Bagby Chair of Prostate Cancer Research
    • OHSU Knight Cancer Institute Deputy Director OHSU Knight Cancer Institute School of Medicine
    • Chief Medical Officer, CEDAR OHSU Knight Cancer Institute School of Medicine
    • Cancer Biology Graduate Program School of Medicine

Dr. Beer’s major research interests include clinical trials, preclinical investigation and risk factors in prostate cancer. His program investigates a broad range of novel agents for prostate cancer, including immune therapies, nutritional supplements, hormonal agents, chemotherapy drugs and target biologic drugs that seek to exploit prostate cancer’s unique vulnerabilities.

Dr. Beer’s clinical research program is tightly linked with laboratory investigations designed to reveal new treatment targets and strategies.

Read more

Education

  • M.D., The Johns Hopkins University, Baltimore Maryland 1991
  • Residency:

    • Oregon Health & Science University, Portland
  • Fellowship:

    • Hematology and Medical oncology, Oregon Health & Science University, Portland
  • Certifications:

    • Oncology

Memberships and associations

  • American College of Physicians
  • Oregon Medical Association
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • Southwest Oncology Group
  • American Urological Association

Publications

  • "Cancer clinical trials of tomorrow" Scientist April 2013
  • "Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer" British Journal of Cancer August 21 2012
  • "Polymorphisms of GSTT1 and related genes in head and neck cancer risk" Head and Neck January 2004
  • "Syndrome of inappropriate antidiuretic hormone secretion" Journal of Urology  2001
  • "Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma" Clinical Genitourinary Cancer  2014
  • "Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer" Clinical Genitourinary Cancer March 2012
  • "Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy" Anticancer Research March 2011
  • "Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer" British Journal of Cancer October 18 2004
  • "Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy" Journal of Clinical Oncology June 10 2009
  • "Management of patients with advanced prostate cancer" Annals of Oncology  2015
  • "ASCENT" BJU International September 2005
  • "The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D 3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells" Clinical Cancer Research June 1 2008
  • "Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole" Breast Cancer Research and Treatment October 2006
  • "Interest in physician-assisted suicide among Oregon cancer patients" Journal of Clinical Ethics March 2006
  • "Prostate Specific Antigen Only Androgen Independent Prostate Cancer" Journal of Urology September 2007
  • "Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer" Expert Opinion on Pharmacotherapy April 1 2015
  • "Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy" Archives of Physical Medicine and Rehabilitation January 1 2015
  • "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043)" The Lancet Oncology  2014
  • "CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity" Prostate March 1 2010
  • "Fine-needle aspiration diagnosis of plasmacytoma presenting as breast masses in a patient on estrogen therapy for prostate cancer" Diagnostic Cytopathology December 2004
  • "Development of a second-generation antiandrogen for treatment of advanced prostate cancer" Science May 8 2009
  • "Optimal timing of chemotherapy in androgen independent prostate cancer" Urologic Oncology: Seminars and Original Investigations January 2009
  • "Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer" Journal of Cancer Research October 15 2010
  • "Views on Physician-Assisted Suicide Among Family Members of Oregon Cancer Patients" Journal of Pain and Symptom Management September 2006
  • "Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of catcitriol, in patients with cancer" Clinical Cancer Research November 1 2005
  • "Phase I Study of Weekly Mitoxantrone and Docetaxel before Prostatectomy in Patients with High-Risk Localized Prostate Cancer" Clinical Cancer Research February 15 2004
  • "Serum and dietary vitamin D and cardiovascular disease risk in elderly men" Nutrition, Metabolism and Cardiovascular Diseases October 2012
  • "Toward predictors of survival in castration-resistant prostate cancer" Cancer September 1 2011
  • "Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer" Cancer January 15 2008
  • "The hazards of intermediate endpoints" Cancer November 1 2007

Additional information

Edit profile